MaxCyte (MXCT) Aandeel Koers

MaxCyte Inc is a renowned biotechnology company specializing in cell engineering and drug discovery. Founded in 1999, MaxCyte has established a strong presence in the life sciences industry. The company's innovative cell engineering platform, known as Flow Electroporation™ Technology, enables precise genetic modification of cells for various applications, including cell-based therapies, gene editing, and biomanufacturing. With a global customer base and strategic partnerships, MaxCyte continues to advance its technology and contribute to groundbreaking research in the field of biotechnology. MaxCyte Inc has emerged as a key player in shaping the future of personalized medicine and regenerative therapies.

MaxCyte Inc is a biotechnology company specializing in cell-based therapies and life sciences. Their business model revolves around providing innovative solutions for cell engineering and drug development. MaxCyte's proprietary technology enables the efficient delivery of molecules into cells, ensuring targeted genetic modification and enhanced therapeutic efficacy. With a focus on collaborations and licensing agreements, MaxCyte aims to expand its reach across various therapeutic areas, including cancer, vaccines, gene editing, and regenerative medicine. By leveraging their expertise in high-performance cell engineering, MaxCyte Inc strives to revolutionize the field of medicine and contribute to the development of novel treatments.

MaxCyte Inc is primarily active in the biotechnology industry.

MaxCyte Inc has achieved significant milestones in its journey. The company has made remarkable advancements in the field of cell engineering and cutting-edge cell-based therapies. MaxCyte's proprietary technology, Flow Electroporation™, has revolutionized the delivery of nucleic acids, proteins, and cell-based therapeutics. The company has successfully developed a broad range of partnerships and collaborations with renowned pharmaceutical and biotechnology companies worldwide. MaxCyte has also received numerous grants and awards recognizing its contributions to the field. Through continuous innovation and strategic collaborations, MaxCyte Inc continues to strengthen its position as a leading player in the biotechnology industry.

MaxCyte Inc is primarily present in the United States, as it is a Maryland-based biotechnology company. However, the company also has a global presence, with operations and collaborations in various countries and regions worldwide. Some notable regions where MaxCyte Inc has a presence include Europe, Asia-Pacific, and the Middle East. With its versatile cell engineering platform, MaxCyte Inc continues to expand its reach and partnerships internationally, catering to the demands of the biotech industry globally while focusing on its headquarters in the United States.

MaxCyte Inc represents a strong commitment to innovation and scientific excellence. The company values include providing cutting-edge cell engineering solutions and transformative technology for the advancement of healthcare and biotechnology. MaxCyte Inc's corporate philosophy focuses on delivering high-quality products and services, fostering collaboration among researchers, and driving advancements in cell-based therapies and drug discovery. By prioritizing customer satisfaction and continuous improvement, MaxCyte Inc aims to contribute to the progress of life sciences industry.

12 analisten beoordelen het aandeel MaxCyte momenteel: 10 adviseren kopen, 2 houden en 0 verkopen. Voor 2026 verwachten analisten dat MaxCyte een omzet van 31,45 Miljoen USD en winst per aandeel van -0,28 USD behaalt.

MaxCyte Koersdoelstellingen analisten 2026

Omgezet tegen de huidige wisselkoers noteert het aandeel MaxCyte op 0,88 EUR (0,98 USD).

Het aandeel MaxCyte (MXCT) is genoteerd aan 5 beurzen, waaronder: NASDAQ (MXCT), London (MXCT.L), Frankfurt (MYE0.F), München (MYE0.MU).

MaxCyte Inc is an emerging biotechnology company specializing in the development of platform technologies for the rapid and efficient production of therapeutics and vaccines. Its business model is based on selling licenses and providing services to companies in the biotech and pharma industries. The company offers a versatile technology platform for the production of high-quality products with higher throughput and shorter production times. MaxCyte has developed a proprietary technology called electroporation, which allows for the direct transfer of DNA, RNA, proteins, and other molecules into cells. The company offers customers the opportunity to utilize this technology through licensing agreements to manufacture their own products or develop new therapeutic candidates. MaxCyte is divided into two business segments: Services and Products. The Services segment offers a range of customized services, from product development to the manufacture of clinical compounds. The Products segment includes various products based on the electroporation-based technology platform. MaxCyte also has partnerships with several major pharmaceutical and biotechnology companies to integrate its technology platform into the development and production of new product candidates. Overall, MaxCyte's business model focuses on the development and marketing of effective and efficient platform technologies for the production of therapeutics and vaccines. The company has established a strong network that includes both biotech and pharmaceutical companies. As the demand for state-of-the-art production technologies continues to grow, MaxCyte will play an important role in this field. Answer: MaxCyte Inc is a biotechnology company specializing in the development of platform technologies for the production of therapeutics and vaccines. Its business model is based on selling licenses and providing services to biotech and pharma companies. MaxCyte has a proprietary electroporation technology for transferring molecules into cells. They offer customized services and products based on this technology. The company also has partnerships with major pharma and biotech firms. Overall, MaxCyte aims to develop and market efficient production technologies for therapeutics and vaccines.

De verwachte omzet van MaxCyte bedraagt 31,45 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De verwachte winst van MaxCyte bedraagt -30,05 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van MaxCyte bedraagt momenteel -3,48. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het MaxCyte-aandeel in te schatten.

De koers-omzetverhouding (P/S) van MaxCyte bedraagt momenteel 3,32. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het MaxCyte-aandeel.

De Eulerpool Kwaliteitsscore voor MaxCyte is 3/10.

De ISIN van MaxCyte is US57777K1060. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van MaxCyte is A2AGVE. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van MaxCyte is MXCT. Onder dit beurstickersymbool wordt het MaxCyte-aandeel op de beurs verhandeld.